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42.3% reported having both NT and EM symptoms, 32.7% reported either 
symptom, and 25.0% reported neither symptom. Mean (±SD) age was 60.2 (±8.0) 
years and the majority of respondents were female (60.5%), white (91.6%), and 
former/current smokers (87.1%). Among respondents with NT symptoms, the 
most commonly reported symptom was coughing (72.9%), followed by wheezing 
(69.2%), and shortness of breath (61.4%). 77.7% of respondents with NT 
symptoms reported sleep disturbance and 59.1% felt anxious due to NT 
symptoms. Among respondents with EM symptoms, the most frequently 
reported symptom was coughing (74.5%), followed by shortness of breath (73.9%), 
and bringing up phlegm or mucus (69.6%). Of respondents with EM symptoms, 
60.4% reported morning activity limitation and 54.3% felt anxious due to EM 
symptoms. CONCLUSIONS: NT/EM symptoms are highly prevalent in the COPD 
population, especially cough and wheezing. The presence of these symptoms 
interferes with patients’ sleep, anxiety, and morning activities.  
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OBJECTIVES: To analyze subjects’ interpretation of concepts specific to Chronic 
Obstructive Pulmonary Disorder (COPD) during pilot testing of translated Patient 
Reported Outcomes (PRO) questionnaires. As observed during pilot testing of 
translated COPD questionnaires, COPD-specific concepts were observed to cause 
more comprehension difficulties across languages, compared to observed 
questionnaires for other diseases. Solutions for these comprehension difficulties 
in COPD questionnaires will be explored. METHODS: Pilot testing data for the 
concepts rescue medication, wheezing, the acronym COPD, and chest tightness 
within PROs were analyzed. Testing was conducted with five subjects per 
language for three questionnaires. Subjects were asked to paraphrase the COPD 
questionnaires in their entirety. Suggestions for improved comprehension of 
COPD concepts were explored, resulting from pilot testing data. RESULTS: 
Rescue medication caused difficulty within half of the languages analyzed. To 
improve comprehension, subjects suggested supplementing rescue medication 
with “(fast acting and quick relief medication)” for improved comprehension. 
Wheezing was a problematic concept for Spanish, South African Bantu and Indian 
languages. The subjects’ proposed solution for these languages was 
supplementation of wheezing with “(heavy breathing accompanied by a whistle 
sound).” Use of the COPD acronym proved problematic for 27% of languages. 
Even in languages where an equivalent acronym exists, comprehension issues 
persisted. Subjects suggested expansion of the acronym to “Chronic Obstructive 
Pulmonary Disorder.” Chest tightnesscaused minimal comprehension issues 
which were not significant enough to merit usable suggestions. CONCLUSIONS: 
Following translation of COPD questionnaires, pilot testing in the target language 
is essential, as concepts specific to COPD are found to be difficult.  
Because medical and technical concepts cannot be substituted, supplementation 
with brief definitions for increased comprehension and expansion of  
acronyms is recommended when developing source PRO questionnaires specific 
to COPD.  
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OBJECTIVES: To assess quality of life (QoL) and dyspnea among chronic 
obstructive pulmonary disease (COPD) patients with/without nighttime (NT) 
and/or early morning (EM) symptoms. METHODS: This study was a cross-
sectional patient survey. Administrative claims from the HealthCore Integrated 
Research Database were utilized to identify commercially-insured patients, aged 
≥40 years, with ≥1 medical claim with an ICD-9-CM diagnosis code of COPD or ≥1 
pharmacy claim for COPD maintenance medication between September 1, 2010-
August 31, 2011. Consenting respondents completed a 25-minute survey that 
included screening questions classifying them as having NT/EM symptoms based 
on whether they experienced symptoms ≥3 nights/mornings in the past week. 
An attempt was made to maximize balance across groups with patients 
qualifying for closed groups being terminated. Patient-reported outcomes 
included the Short Form-12 version 2 (SF-12v2), the COPD Assessment Test 
(CAT), and the modified Medical Research Council (mMRC) dyspnea scale. 
Analysis of variance and chi-square were used to evaluate outcome differences 
among symptom groups. RESULTS: Of 752 respondents completing the survey, 
42.3% reported having both NT/EM symptoms, 32.7% reported either NT or EM 
symptoms, and 25.0% reported neither symptoms. Mean (±SD) age was 60.2 (±8.0) 
years and the majority of respondents were female (60.5%), white (91.6%), and 
former/current smokers (87.1%). Compared to respondents without symptoms, 
those with both or either NT/EM symptoms reported worse QoL and dyspnea as 
indicated by significantly lower SF-12v2 Physical Component Summary (PCS) and 
Mental Component Summary (MCS) mean scores (PCS: 34.0 vs 38.6 vs 43.8, 
p<0.01; MCS: 47.0 vs 52.8 vs 54.3, p<0.01), as well as higher CAT and mMRC mean 
scores (CAT: 21.6 vs 13.8 vs 9.1, p<0.01; mMRC: 1.8 vs 1.1 vs 0.8, p<0.01). 
CONCLUSIONS: COPD patients with NT/EM symptoms reported worse QoL and 
dyspnea scores compared with patients without symptoms. Improved 
management of NT/EM symptoms may decrease the burden associated with 
these symptoms.  
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OBJECTIVES: In the USA, chronic cough (CC) is the most common complaint for 
which patients seek medical attention (McGarvey, 2007). When assessing new 
treatments for CC in clinical trials, patient reported outcomes (PROs) are 
important methodologies for evaluating effectiveness. The objective of this 
literature review was to identify validated PRO instruments that can assess 
patients’ experience of (new) cough therapies in idiopathic chronic cough (ICC) 
and CC in chronic obstructive pulmonary disease (COPD), idiopathic pulmonary 
fibrosis (IPF) and lung cancer. METHODS: Literature search according to pre-
defined strategy and review criteria was performed in multiple databases. This 
search resulted in 33 included full-texts from which 9 relevant PROs were 
identified. RESULTS: The main questionnaires investigated in the included 
publications were the Leicester Cough Questionnaire (LCQ), the Chronic Cough 
Impact Questionnaire (CCIQ), and the Cough Visual Analogue Scale (VAS). Other 
cough specific PROs reviewed were the Cough Quality of Life Questionnaire 
(CQLQ), the Cough Symptom Diary (CSD) and the Adverse Cough Outcome 
Survey (ACOS). Some cough relevant items were included in the Breathlessness 
Cough and Sputum Scale (BCSS), the St. George’s Respiratory Questionnaire 
(SGRQ) and the Cough and Sputum Assessment Questionnaire (CASAQ). All 
instruments are relatively new and need further content validity, responsiveness 
and interpretability testing. Overall, the LCQ was the most psychometrically 
sound. The CSD has potential to be a high quality measure; it is the only PRO 
that provided a conceptual framework and measures cough severity; however, 
some major aspects still need to be validated. No questionnaire has been 
developed specifically for the population of interest; and few have been validated 
within this population. CONCLUSIONS: Several relevant instruments for ICC and 
CC trials exist, but they are relatively new and need further validation. The two 
most promising PROs are the LCQ for disease-specific quality-of-life and the CSD 
for cough severity.  
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OBJECTIVES: To describe the design and execution of a hybrid, cross-sectional 
study of COPD patients, highlighting important strengths, weaknesses, and 
general considerations for use in burden of illness and health economic 
analyses. METHODS: A cross-sectional, observational study of 407 COPD patients 
was conducted in 3 centers in the southeastern region of the U.S. This hybrid 
study combined a cross-sectional patient survey and retrospective chart review. 
All patients diagnosed with COPD managed by a primary care physician (PCP) or 
pulmonologist who had their most recent visit within the eligibility period were 
invited to complete a baseline survey; chart data was abstracted by site medical 
staff for all patients who consented and completed the survey. Each clinic 
enrolled patients in 2 cohorts: COPD patients managed primarily by a PCP 
(N=152; male: 49.3 %; mean age: 70.9±9.5 years) veersus pulmonologist (N=255; 
male: 50.6%; mean age: 71.2±8.9 years). Anonymized patient data was recorded 
in a secure web-based database: demographics, clinical characteristics, COPD 
exacerbations and severity, resource utilization, treatment, symptoms, daily 
functioning, and quality of life. Key design challenges related primarily to patient 
recruitment: identifying a PCP versus pulmonologist for patient subgroup 
assignment; identification of COPD patients through comprehensive medical 
chart review; mitigation of selection bias for severe COPD cases that are more 
likely to visit an HCP for COPD-related reasons only; missing medical chart data; 
and temporality and causality associated with study outcomes. RESULTS: The 
key operational challenges were maximizing survey response rates and 
completeness of chart review with limited possibility of follow-up. 
CONCLUSIONS: Cross-sectional design is an efficient method of collecting data 
in COPD patients that could be used for health services research. However, it is 
associated with design and operational challenges that can be anticipated and 
mitigated early in study planning and conceptualization.  
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OBJECTIVES: Atopic dermatitis (AD) is a common chronic skin condition in 
childhood that has negative impact on both patients and their families. A survey 
was conducted to evaluate the disease burden, quality of life (QOL) and financial 
impact of moderate to severe pediatric AD in the Asia Pacific region. This 
analysis focuses on the QOL impact of pediatric AD. METHODS: A cross sectional 
online survey was conducted among 1028 parents of children with moderate to 
severe AD in 12 countries: Australia, China, Hong Kong, India, Indonesia, Korea, 
Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam. The Infant’s 
Dermatitis Quality of Life Index (IDQOL) was used for children less than 4 years 
old and the Children’s Dermatology Life Quality Index (CDLQI) for those aged 
between 4 to 16 years. The Dermatitis Family Impact (DFI) was used to assess the 
impact on family life. The maximum score for all three questionnaires is 30, 
categorized into 5 effect groups; none (0-1), small (2-6), moderate (7-12), very 
